Discussion on the Efficacy and Safety of Sitagliptin Combined with Englitazone in the Treatment of Refractory Diabetes  

作　　者：ZHANGXiubin 

机构地区：[1]Cangzhou Nandagang Hospital, Cangzhou Hebei 061103, China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第9期076-080,共5页

摘　　要：Objective: to explore the effect of treatment with enaglitazone in patients with refractory diabetes during the period of taking sitagliptin. Methods: 100 patients with refractory diabetes were selected. The receiving period was from March 2020 to March 2022. According to the relevant standards of "random number table method", standardized random grouping was carried out. For the 50 cases in the control group who were included in the study group, the single dose regimen of sitagliptin was used, while the 50 cases in the observation group were added with engegligin on the basis of sitagliptin. Results: the total effective rate was 96.00% in the observation group and 76.00% in the control group. The former group was higher than the latter group (P0.05);after observing the time of reaching the blood glucose standard and the amount of insulin used in the two groups involved in the study, the observation group was at a lower level (P0.05);before each treatment, the blood glucose index, islet function index, blood lipid index, inflammatory factor, renal function index and the measured value of homocysteine (Hcy) in the two groups were evaluated, and there was no significant difference (P>0.05). After the completion of each treatment, the levels of the above indicators were measured, except islets β cell function index (HOMA- β)、high density lipoprotein (HDL-C) showed an increase, and the measured values of other indicators showed a decrease, especially in the observation group (P0.05);through the observation of the rate of adverse reactions such as fatigue and hypoglycemia in the two groups, the observation group was at a lower level (P0.05). Conclusion: for patients with refractory diabetes, treatment with sitagliptin combined with engliflozin can improve the total clinical effective rate, shorten the time for blood glucose to reach the standard, reduce the amount of insulin, and improve blood glucose, blood lipid, pancreatic islet function, renal function and other indicators, without obvious adverse drug reactio

关 键 词：sigliptin engelgin refractory diabetes EFFECTIVENESS SECURITY 

分 类 号：R587.1[医药卫生—内分泌]